MiMedx Group, Inc. (NASDAQ:MDXG) Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA reduced its position in MiMedx Group, Inc. (NASDAQ:MDXG) by 2.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 173,743 shares of the company’s stock after selling 5,189 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.12% of MiMedx Group worth $1,671,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of MDXG. Norges Bank acquired a new position in MiMedx Group in the 4th quarter valued at about $4,020,000. JPMorgan Chase & Co. boosted its holdings in MiMedx Group by 133.1% during the fourth quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company’s stock worth $6,668,000 after buying an additional 395,739 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in MiMedx Group by 484.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company’s stock worth $3,487,000 after buying an additional 300,433 shares during the period. Jane Street Group LLC increased its holdings in MiMedx Group by 133.6% in the third quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock valued at $1,806,000 after buying an additional 174,797 shares in the last quarter. Finally, Barclays PLC lifted its position in shares of MiMedx Group by 163.9% during the 3rd quarter. Barclays PLC now owns 262,449 shares of the company’s stock valued at $1,550,000 after acquiring an additional 163,005 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Trading Down 3.2 %

Shares of MiMedx Group stock opened at $6.86 on Wednesday. The business has a 50 day moving average price of $7.99 and a 200 day moving average price of $7.97. The company has a market capitalization of $1.01 billion, a P/E ratio of 12.47 and a beta of 1.74. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.07. The company had revenue of $92.91 million during the quarter, compared to analysts’ expectations of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Sell-side analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Analyst Ratings Changes

MDXG has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th. StockNews.com upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 4th.

Insiders Place Their Bets

In related news, CAO William Frank Iv Hulse sold 54,596 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $430,762.44. Following the transaction, the chief accounting officer now owns 440,178 shares of the company’s stock, valued at approximately $3,473,004.42. This represents a 11.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the sale, the insider now directly owns 310,836 shares of the company’s stock, valued at $2,452,496.04. The trade was a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 144,018 shares of company stock valued at $1,130,312 in the last ninety days. Insiders own 1.30% of the company’s stock.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.